Critical Cancer Research - on demand
Time-sensitive and reliable cancer news, research and analysis
covering clinical trials, drugs, treatments and cures worldwide
| For 24/7 unlimited access... | |
|---|---|
Subscribe now
|
or call us on: +43 (0)1 71 72 8 900 (Vienna) or on: +44 (0)20 7769 6707 (London) |
Pricing
Our pricing options are simple. There is one structure for corporates/professionals, and another special discounted structure for patients and their family.
1. Corporates/Professionals (Healthcare & Pharmaceutical)
For corporates/professionals the service costs €660/£600 a year per user. This works out at €55/£50 a month per user.
Corporates/professionals can subscribe to Cancer Stat by contacting us directly:
- by email: cancerstat@templetonapus.com
- by phone:
Vienna office, Austria, European Union: +43 (0)1 71 71 8 900
London office, United Kingdom: +44 (0)20 7769 6707
You have the option of taking a 2 week free trial to Cancer Stat before subscribing.
2. Patients/Family
Patients/family can subscribe to Cancer Stat at a special discounted rate by either of the following methods:
a. Making a single payment of £240 for a year's subscription via PayPal.
b. Paying £30 a month for an ongoing monthly subscription via PayPal.
Both options provide you with your own personal Cancer Stat account and can be found at: www.cancerstat.com/accounts/subscribe
You will have full access to all platform features and to the extensive email services. You can also request that drugs or treatments that are of special interest to you are added and tracked.
After signing up:
1. You will receive by email your login ID and password within 3 hours.
2. The email will include a weblink with a 10 minute video demo explaining how to most effectively use your Cancer Stat account.
3. You will be asked in the email if you have any specific information content requests.
Payments
1. Corporates/Professionals (Healthcare & Pharmaceutical)
Corporates/professionals will be invoiced.
2. Patients/Family
Patients/family can make secure payments using credit or debit cards via PayPal at: www.cancerstat.com/accounts/subscribe
Most viewed
- 1. Iomab-ACT: A Pilot Study of 131-I Apamistamab (Iomab-B) Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
- 2. Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant
- 3. Seoul Viosys to Develop a Cancer Diagnosis Technology for Companion Animals with Violeds Technology
- 4. Nivolumab Plus Chemotherapy Improves Survival Outcomes in Gastric and Esophageal Cancers
- 5. Heavy class A drug use linked to heightened risk of sight loss in US military
- 6. Smoking strongly linked to women's lower take up of cancer screening services
- 7. Trouble With Daily Activities Tied to Worse Cancer Outcomes
- 8. Mission Bio Lands $70M to Expand Cancer Therapies With Single-Cell Multi-Omics Platform
- 9. Babyteeth: The teen film tackling cancer with humour
- 10. FDA to decide on TG Therapeutics' lymphoma drug early next year
Last updated at 4:36 GMT
Hot News Makers
Health/Pharma Companies
-
58638.06
-
46698.55
-
39226.19
-
36264.68
-
31212.88
-
14558.00
-
11992.58
-
11546.35
-
11124.80
-
10716.03
Last updated at 4:10 GMT
© Copyright 2020 Templeton Apus. All rights reserved.
Made with 
and
in the EU & the UK
and
in the EU & the UK